Поиск | Myliveroom — Live Events & Online Communities

Rohit More добавлена новая статья Другое
2026-06-12 10:28:29 - Перевод -

Adalimumab Biosimilar Market Size, Share, Growth Trends, Industry Analysis, and Forecast 2026–2032
According to the latest report published by Data Bridge Market Research, the Adalimumab Biosimilar Market Data Bridge Market Research analyses that the adalimumab biosimilar market which is USD 598.30 million in 2022, is expected to reach USD 3431.48 million by 2030, at a CAGR of 24.4% during the forecast period 2023 to 2030. The large scale Adalimumab Biosimilar Marketing report...

0 Комментарии 0 Поделились 136 Просмотры 0 предпросмотр

Войдите, чтобы отмечать, делиться и комментировать!
Sameer Shewale добавлена новая статья Активировано
2026-05-04 07:47:54 - Перевод -

Anti-Rheumatics Market Size to Reach USD 84.18 Billion by 2033, Driven by Rising Prevalence of Autoimmune Disorders
Market Overview The global Anti-Rheumatics Market is witnessing steady growth, driven by the increasing prevalence of autoimmune diseases such as rheumatoid arthritis and other inflammatory conditions. According to the latest report by Straits Research, the market was valued at USD 66.24 billion in 2024 and is projected to reach USD 84.18 billion by 2033, growing at a CAGR of 2.7% during...

0 Комментарии 0 Поделились 535 Просмотры 0 предпросмотр

Войдите, чтобы отмечать, делиться и комментировать!
Rohit More добавлена новая статья Другое
2026-06-12 10:49:02 - Перевод -

Janus Kinase (JAK) Inhibitor Drugs Market Size, Share, Growth Trends, Industry Analysis, and Forecast 2026–2032
According to the latest report published by Data Bridge Market Research, the Janus Kinases (JAKs) Inhibitor Drugs Market Data Bridge Market Research analyses that the Janus kinases (JAKs) inhibitor drugs market, which is USD 2.45 billion in 2022, is expected to reach USD 5.11 billion by 2030, at a CAGR of 9.6% during the forecast period 2023 to 2030. To impart a supreme quality to...

0 Комментарии 0 Поделились 114 Просмотры 0 предпросмотр

Войдите, чтобы отмечать, делиться и комментировать!